Pyxis Oncology Inc (PYXS) FinancialsPYXSPyxis Oncology Inc

Evaluating the bottom line, Pyxis Oncology Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -179.10%, provide a clear picture of how effectively PYXS converts its operational activities into shareholder value.

In the context of the broader market, PYXS competes directly with industry leaders such as IKT and SIGA. With a market capitalization of $193.42M, it holds a significant position in the sector. When comparing efficiency, PYXS's gross margin of N/A stands against IKT's N/A and SIGA's 57.17%. Such benchmarking helps identify whether Pyxis Oncology Inc is trading at a premium or discount relative to its financial performance.

Total revenue for Q2 2025 was $2.82 million, but the company has been reporting significant net losses, with Q2 2026 projected net income of -$25.35 million. The gross margin for Q2 2025 was 100%, indicating potential profitability if revenues increase.